Chronic Lower Back Pain Epidemiology Forecast

DelveInsight's 'Chronic Lower Back Pain - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Lower Back Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Chronic Lower Back Pain Understanding

The DelveInsight Chronic Lower Back Pain epidemiology report gives a thorough understanding of the Chronic Lower Back Pain by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Chronic Lower Back Pain in the US, Europe, and Japan. The report covers the detailed information of the Chronic Lower Back Pain epidemiology scenario in seven major countries (US, EU5, and Japan).


Chronic Lower Back Pain Epidemiology Perspective by DelveInsight

The Chronic Lower Back Pain epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chronic Lower Back Pain epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chronic Lower Back Pain epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Chronic Lower Back Pain Detailed Epidemiology Segmentation

The Chronic Lower Back Pain epidemiology covered in the report provides historical as well as forecasted Chronic Lower Back Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Chronic Lower Back Pain report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Chronic Lower Back Pain report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Chronic Lower Back Pain Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic Lower Back Pain in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Chronic Lower Back Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic Lower Back Pain
  • The report provides the segmentation of the Chronic Lower Back Pain epidemiology


Report Highlights

  • 11-Year Forecast of Chronic Lower Back Pain epidemiology
  • 7MM Coverage
  • Total Cases of Chronic Lower Back Pain
  • Total Cases of Chronic Lower Back Pain according to segmentation
  • Diagnosed cases of Chronic Lower Back Pain


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Lower Back Pain?
  • What are the key findings pertaining to the Chronic Lower Back Pain epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Chronic Lower Back Pain across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Chronic Lower Back Pain?
  • What are the currently available treatments of Chronic Lower Back Pain?


Reasons to buy

  • The Chronic Lower Back Pain Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Chronic Lower Back Pain market
  • Quantify patient populations in the global Chronic Lower Back Pain market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Lower Back Pain therapeutics in each of the markets covered
  • Understand the magnitude of Chronic Lower Back Pain population by its epidemiology
  • The Chronic Lower Back Pain Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1 Key Insights

2 Chronic Lower Back Pain (CLBP) Epidemiology Overview at a Glance

2.1 Epidemiology (%) Distribution of CLBP in 2017

2.2 Epidemiology (%) Distribution of CLBP in 2030

3 Executive Summary

4 SWOT Analysis

5 Chronic Lower Back Pain (CLBP): Disease Background and Overview

5.1 Introduction

5.2 Signs and Symptoms

5.3 Causes and Risk Factors

5.4 Genetics of Chronic Lower Back Pain

5.5 Pathophysiology

5.5.1 Degenerative Cascade

5.5.2 Mechanistic factors involved behind the cause of CLBP

5.5.3 Neuroplasticity and central sensitization

5.5.4 Connective tissue remodeling in CLBP

5.5.5 Effect of connective tissue pathology on sensory afferent modulation

5.5.6 CLBP and Connective Tissue Remodeling

5.5.7 Pathophysiological model

5.6 Type of pain

5.6.1 Diskogenic pain

5.6.2 Lumbar spinal stenosis

5.6.3 Sacroiliac pain

5.6.4 Facet-joint pain

5.6.5 Radicular pain

5.6.6 Muscular pain

5.7 Diagnosis

5.7.1 Clinical History

5.7.2 Physical Examination

5.7.3 Imaging Guidelines

5.7.4 Assessment of Pain

6 Epidemiology Methodology

7 Epidemiology and Patient Population

7.1. Key Findings

7.2. Total Prevalent Population of Chronic Lower Back Pain in the 7MM

7.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM

7.4. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM

7.5. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM

7.6. Severity Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM

8 United States Epidemiology

8.1. Total Prevalent Population of Chronic Lower Back Pain in the United States

8.2. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States

8.3. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States

8.4. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States

8.5. Severity Specific Diagnosed Prevalence of CLBP in the United States

8.6. Number of CLBP Patients on Prescription Medications by different Class in the United States

8.7. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United States

9 EU5 Epidemiology

9.1. Germany Epidemiology

9.1.1. Total Prevalent Population of Chronic Lower Back Pain in Germany

9.1.2. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany

9.1.3. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany

9.1.4. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany

9.1.5. Severity Specific Diagnosed Prevalence of CLBP in Germany

9.1.6. Number of CLBP Patients on Prescription Medications by different Class in Germany

9.1.7. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany

9.2. France Epidemiology

9.2.1. Total Prevalent Population of Chronic Lower Back Pain in France

9.2.2. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France

9.2.3. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in France

9.2.4. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in France

9.2.5. Severity Specific Diagnosed Prevalence of CLBP in France

9.2.6. Number of CLBP Patients on Prescription Medications by different Class in France

9.2.7. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France

9.3. Italy Epidemiology

9.3.1. Total Prevalent Population of Chronic Lower Back Pain in Italy

9.3.2. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy

9.3.3. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy

9.3.4. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy

9.3.5. Severity Specific Diagnosed Prevalence of CLBP in Italy

9.3.6. Number of CLBP Patients on Prescription Medications by different Class in Italy

9.3.7. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy

9.4. Spain Epidemiology

9.4.1. Total Prevalent Population of Chronic Lower Back Pain in Spain

9.4.2. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain

9.4.3. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain

9.4.4. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain

9.4.5. Severity Specific Diagnosed Prevalence of CLBP in Spain

9.4.6. Number of CLBP Patients on Prescription Medications by different Class in Spain

9.4.7. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain

9.5. United Kingdom Epidemiology

9.5.1. Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom

9.5.2. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom

9.5.3. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom

9.5.4. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom

9.5.5. Severity Specific Diagnosed Prevalence of CLBP in the United Kingdom

9.5.6. Number of CLBP Patients on Prescription Medications by different Class in the United Kingdom

9.5.7. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United Kingdom

10 Japan Epidemiology

10.1. Total Prevalent Population of Chronic Lower Back Pain in Japan

10.2. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan

10.3. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan

10.4. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan

10.5. Severity Specific Diagnosed Prevalence of CLBP in Japan

10.6. Number of CLBP Patients on Prescription Medications by different Class in the Japan

10.7. Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the Japan

11 Appendix

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight

Table 1: Risk factors for occurrence and chronicity of low back pain

Table 2: Cause of Muscle connective tissue fibrosis

Table 3: Total Prevalent Population of Chronic Lower Back Pain in the 7MM (2017–2030)

Table 4: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM (2017─2030)

Table 5: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017─2030)

Table 6: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017─2030)

Table 7: Severity Specific Diagnosed Prevalence of CLBP in the 7MM (2017─2030)

Table 8: Total Prevalent Population of Chronic Lower Back Pain in the US (2017─2030)

Table 9: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the US (2017─2030)

Table 10: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2017─2030)

Table 11: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2017─2030)

Table 12: Severity Specific Diagnosed Prevalence of CLBP in the US (2017─2030)

Table 13: Number of CLBP Patients on Prescription Medications by different Class in the US (2017─2030)

Table 14: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the US (2017─2030)

Table 15: Total Prevalent Population of Chronic Lower Back Pain in Germany (2017─2030)

Table 16: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany (2017─2030)

Table 17: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017─2030)

Table 18: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017─2030)

Table 19: Severity Specific Diagnosed Prevalence of CLBP in Germany (2017─2030)

Table 20: Number of CLBP Patients on Prescription Medications by different Class in Germany (2017─2030)

Table 21: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany (2017─2030)

Table 22: Total Prevalent Population of Chronic Lower Back Pain in France (2017─2030)

Table 23: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France (2017─2030)

Table 24: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017─2030)

Table 25: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017─2030)

Table 26: Severity Specific Diagnosed Prevalence of CLBP in France (2017─2030)

Table 27: Number of CLBP Patients on Prescription Medications by different Class in France (2017─2030)

Table 28: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France (2017─2030)

Table 29: Total Prevalent Population of Chronic Lower Back Pain in Italy (2017─2030)

Table 30: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy (2017─2030)

Table 31: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017─2030)

Table 32: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017─2030)

Table 33: Severity Specific Diagnosed Prevalence of CLBP in the Italy (2017─2030)

Table 34: Number of CLBP Patients on Prescription Medications by different Class in Italy (2017─2030)

Table 35: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy (2017─2030)

Table 36: Total Prevalent Population of Chronic Lower Back Pain in Spain (2017─2030)

Table 37: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain (2017─2030)

Table 38: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017─2030)

Table 39: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017─2030)

Table 40: Severity Specific Diagnosed Prevalence of CLBP in the Spain (2017─2030)

Table 41: Number of CLBP Patients on Prescription Medications by different Class in Spain (2017─2030)

Table 42: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain (2017─2030)

Table 43: Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Table 44: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Table 45: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Table 46: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Table 47: Severity Specific Diagnosed Prevalence of CLBP in the United Kingdom (2017─2030)

Table 48: Number of CLBP Patients on Prescription Medications by different Class in the United Kingdom (2017─2030)

Table 49: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United Kingdom (2017─2030)

Table 50: Total Prevalent Population of Chronic Lower Back Pain in Japan (2017─2030)

Table 51: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2017─2030)

Table 52: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017─2030)

Table 53: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017─2030)

Table 54: Severity Specific Diagnosed Prevalence of CLBP in Japan (2017─2030)

Table 55: Number of CLBP Patients on Prescription Medications by different Class in Japan (2017─2030)

Table 56: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Japan (2017─2030)

Figure 1: Types of Lower Back Pain

Figure 2: Signs and Symptoms of CLBP

Figure 3: Pathophysiological model for chronic low back pain linking somatic and behavioral components

Figure 4: Relationship describing therapeutic inventions and pathogenic mechanism

Figure 5: Types of Pain involved in CLBP mechanism

Figure 6: Definitions of Chronic Lower Back Pain

Figure 7: Total Prevalent Population of Chronic Lower Back Pain in the 7MM (2017─2030)

Figure 8: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM (2017─2030)

Figure 9: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017─2030)

Figure 10: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM (2017─2030)

Figure 11: Severity Specific Diagnosed Prevalence of CLBP in the 7MM (2017─2030)

Figure 12: Total Prevalent Population of Chronic Lower Back Pain in the US (2017─2030)

Figure 13: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the US (2017─2030)

Figure 14: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2017─2030)

Figure 15: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2017─2030)

Figure 16: Severity Specific Diagnosed Prevalence of CLBP in the US (2017─2030)

Figure 17: Number of CLBP Patients on Prescription Medications by different Class in the US (2017─2030)

Figure 18: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the US (2017─2030)

Figure 19: Total Prevalent Population of Chronic Lower Back Pain in Germany (2017─2030)

Figure 20: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Germany (2017─2030)

Figure 21: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017─2030)

Figure 22: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Germany (2017─2030)

Figure 23: Severity Specific Diagnosed Prevalence of CLBP in Germany (2017─2030)

Figure 24: Number of CLBP Patients on Prescription Medications by different Class in Germany (2017─2030)

Figure 25: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Germany (2017─2030)

Figure 26: Total Prevalent Population of Chronic Lower Back Pain in France (2017─2030)

Figure 27: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in France (2017─2030)

Figure 28: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017─2030)

Figure 29: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in France (2017─2030)

Figure 30: Severity Specific Diagnosed Prevalence of CLBP in France (2017─2030)

Figure 31: Number of CLBP Patients on Prescription Medications by different Class in France (2017─2030)

Figure 32: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in France (2017─2030)

Figure 33: Total Prevalent Population of Chronic Lower Back Pain in Italy (2017─2030)

Figure 34: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Italy (2017─2030)

Figure 35: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017─2030)

Figure 36: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Italy (2017─2030)

Figure 37: Severity Specific Diagnosed Prevalence of CLBP in Italy (2017─2030)

Figure 38: Number of CLBP Patients on Prescription Medications by different Class in Italy (2017─2030)

Figure 39: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Italy (2017─2030)

Figure 40: Total Prevalent Population of Chronic Lower Back Pain in Spain (2017─2030)

Figure 41: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Spain (2017─2030)

Figure 42: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017─2030)

Figure 43: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in Spain (2017─2030)

Figure 44: Severity Specific Diagnosed Prevalence of CLBP in Spain (2017─2030)

Figure 45: Number of CLBP Patients on Prescription Medications by different Class in Spain (2017─2030)

Figure 46: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Spain (2017─2030)

Figure 47: Total Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Figure 48: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Figure 49: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Figure 50: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the United Kingdom (2017─2030)

Figure 51: Severity Specific Diagnosed Prevalence of CLBP in the United Kingdom (2017─2030)

Figure 52: Number of CLBP Patients on Prescription Medications by different Class in the UK (2017─2030)

Figure 53: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in the United Kingdom (2017─2030)

Figure 54: Total Prevalent Population of Chronic Lower Back Pain in Japan (2017─2030)

Figure 55: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2017─2030)

Figure 56: Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2017─2030)

Figure 57: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain CLBP in Japan (2017─2030)

Figure 58: Severity Specific Diagnosed Prevalence of CLBP in Japan (2017─2030)

Figure 59: Number of CLBP Patients on Prescription Medications by different Class in Japan (2017─2030)

Figure 60: Number of CLBP Patients on Opioids by low dose, high dose & Overdose in Japan (2017─2030)

  • Tags:
  • Chronic Lower Back Pain Epidemiolog...
  • Chronic Lower Back Pain
  • Chronic Lower Back Pain Pipeline
  • Chronic Lower Back Pain Companies
  • Chronic Lower Back Pain prevalent...
  • Chronic Lower Back Pain incident p...
  • Chronic Lower Back Pain patients d...
  • Chronic Lower Back Pain treatment...

Forward to Friend

Need A Quote